Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Non-profit
  • Arts
  • Education
  • Technology
  • Books
ncarol.com

Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
ncarol.com/10174876

Trending...
  • SPJ's Green Eyeshade Awards Journalism Competition, Celebrating 75 Years, Announces 2025 Honors
  • Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
  • GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will present at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. Eastern Time in New York City, NY.



Date:





June 10, 2022



Presentation Time:





10:30 a.m. ET



Webcast:





http://investors.aeriepharma.com



Replay Availability:





Until September 8, 2022


About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie's first novel product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rhopressa®, including the product label, is available at www.rhopressa.com. Aerie's second novel product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain and conjunctival hemorrhage. More information about Rocklatan®, including the product label, is available at www.rocklatan.com. More information on Aerie Pharmaceuticals is available at www.aeriepharma.com.

More on ncarol.com
  • Rent Like A Champion Acquires CollegeWeekends
  • First Flight Society Celebrates National Aviation Day 2025 on Tuesday, August 19th
  • Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
  • Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
  • Free Marketing Book Saves Brands from Being Ignored

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "exploring," "pursuing" or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements in this release include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our commercial franchise and our pipeline, any guidance or timelines and our ongoing and anticipated preclinical studies and clinical trials. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, industry change and other factors beyond our control, and depend on regulatory approvals and economic and other environmental circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these risks in greater detail under the heading "Risk Factors" in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

More on ncarol.com
  • databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
  • AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
  • WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
  • CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
  • Nonprofit innovator named Mensa Executive Director

Contacts

Media:
Carolyn McAuliffe
cmcauliffe@aeriepharma.com
(949) 526-8733

Investors:
LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.
Hans Vitzthum
hans@lifesciadvisors.com
(617) 430-7578
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Ironside HR Named Fastest-Growing Staffing Firm for Second Year
  • Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
  • ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
  • Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
  • Duke Energy announces dividend payments to shareholders
  • $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
  • Financial Educator Nadia Vanderhall Featured On GMA To Share Real-Life Budgeting Insights
  • Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
  • New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
  • SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
  • TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
  • Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
  • KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
  • The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
  • Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
  • Secrets in the Himalayas: Author K.A. Nayampalli Comes to Barnes & Noble Huntersville
  • Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
  • GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
_catLbl0 _catLbl1

Popular on ncarol.com

  • A Family Affair: Abernethy Laurels Hosts a Wedding with Heart - 110
  • Jeopardy!'s Ken Jennings Headlines National Mensa Event - 108
  • OPRAH.COM Featured Award-Winning Novel AS FAR AS YOU GO BEFORE YOU HAVE TO COME BACK now Available as Audiobook - 103
  • Mensa Foundation Prize Awarded to Neuroscientist-Pianist - 103
  • KeysCaribbean Vacation Home Rentals Offers Last-Minute Booking Discount of 15 Percent
  • Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
  • databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
  • Dr. Jacqueline West Honored as Best Dentist in JAX by Folio Weekly

Similar on ncarol.com

  • Pixel Studio Productions Launches Same-Day Headshots in Houston
  • SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
  • Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
  • databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
  • AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
  • WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
  • Nonprofit innovator named Mensa Executive Director
  • Yasmine Roulleau named Managing Director in Vancouver, Canada
  • Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
  • Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute